Alector, Inc. (ALEC) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 TranscriptSeeking Alpha • 12/08/25
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law FirmGlobeNewsWire • 11/26/25
Alector Stock Plummets 63% in a Month: Here's What You Need to KnowZacks Investment Research • 11/18/25
Alector Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 11/06/25
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/29/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alector, Inc. - ALECPRNewsWire • 10/28/25
Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN TherapeuticGlobeNewsWire • 10/21/25
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business UpdateGlobeNewsWire • 10/21/25
Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier ProgramsGlobeNewsWire • 09/16/25
Alector, Inc. (ALEC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/08/25
Alector Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/25
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewsWire • 06/03/25
Alector Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/08/25
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's DiseaseGlobeNewsWire • 04/17/25